High-dose cytarabine

Phase 3Small molecule

PProtherics Medicines Development Limited

High-dose cytarabine is one of 230 small molecule programs targeting Childhood Acute Lymphoblastic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

229

Competitors

Pipeline

Status by Indication[3][1]

Indication

Childhood Acute Lymphoblastic LeukemiaActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Central Nervous System LymphomaActive, not recruiting

OsteosarcomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Leptomeningeal MetastasisActive, not recruiting

Childhood Acute Lymphoblastic LeukemiaPreclinical

Active, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Central Nervous System LymphomaPhase 2

Active, not recruiting

OsteosarcomaPhase 3

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Mantle Cell LymphomaPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Leptomeningeal MetastasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Tibsovo

SServier

Phase 3

8 2

Retin-a

VValeant Pharmaceuticals

Phase 3

2 3

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Lenograstim

Sanofi

Phase 3

1 5

Campath

GGenzyme, a Sanofi Company

Phase 3

—6

High-dose cytarabine

PProtherics Medicines Development Limited

Phase 3

1 7

Sapacitabine

CCyclacel Pharmaceuticals, Inc.

Phase 3

1 8

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Phase 3

1 9

Recombinant FLT3 Ligand

EEastern Cooperative Oncology Group

Phase 3

1 10

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Metastatic Breast Cancer

NCT02422641

Clinical

Trials by Indication[1]

Mantle Cell Lymphoma1 trial

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02633137·49 enrolled

Central Nervous System1 trial

High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL

Unknown status·—·Phase 3·NCT03123718·205 enrolled

Acute Lymphoblastic Leukemia1 trial

Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children

Unknown status·TThe Korean Society of Pediatric Hematology Oncology·Phase 2·NCT02339350·110 enrolled

Childhood Acute Lymphoblastic Leukemia1 trial

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·N/A·NCT01953770·3,000 enrolled

Osteosarcoma1 trial

Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma

Completed·TThe Hospital for Sick Children·Phase 3·NCT01176981·6 enrolled

6 more indications

Methotrexate1 trial

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

Unknown status·PProtherics Medicines Development Limited··NCT05899751·1,000 enrolled

T-cell acute lymphoblastic leukemia1 trial

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02518750·3 enrolled

Central Nervous System Lymphoma1 trial

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT00210314·79 enrolled

Prospective1 trial

A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.

Enrolling by invitation·—·Phase 3·NCT03507842·380 enrolled

Acute Myeloid Leukemia1 trial

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

Completed·CCephalon·Phase 2·NCT00079482·224 enrolled

Metastatic Breast Cancer1 trial

Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT02422641·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for High-dose cytarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — High-dose cytarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for High-dose cytarabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Protherics Medicines Development Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PProtherics Medicines Development Limited

High-dose cytarabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Mantle Cell Lymphoma1 trial

Central Nervous System1 trial

Acute Lymphoblastic Leukemia1 trial

Childhood Acute Lymphoblastic Leukemia1 trial

Osteosarcoma1 trial

Methotrexate1 trial

T-cell acute lymphoblastic leukemia1 trial

Central Nervous System Lymphoma1 trial

Prospective1 trial

Acute Myeloid Leukemia1 trial

Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News